P Traxler

Summary

Affiliation: Novartis Institutes for BioMedical Research

Publications

  1. ncbi request reprint Tyrosine kinase inhibitors: from rational design to clinical trials
    P Traxler
    Novartis Pharma AG, Oncology Research, CH 4002 Basel, Switzerland
    Med Res Rev 21:499-512. 2001
  2. ncbi request reprint Tyrosine kinases as targets in cancer therapy - successes and failures
    Peter Traxler
    Novartis Pharma AG, Oncology Research, CH4002 Basel, Switzerland
    Expert Opin Ther Targets 7:215-34. 2003
  3. ncbi request reprint AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity
    Peter Traxler
    Oncology Research, Novartis Institutes for BioMedical Research, Klybeckstrasse, CH 4002 Basel, Switzerland
    Cancer Res 64:4931-41. 2004
  4. ncbi request reprint New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis
    G Bold
    Oncology Research, and Process Research, Novartis Pharma AG, CH 4002 Basel, Switzerland
    J Med Chem 43:2310-23. 2000
  5. ncbi request reprint Protein kinases as targets for anticancer agents: from inhibitors to useful drugs
    Doriano Fabbro
    Department of Oncology, Novartis Pharma Inc, WKL 125 4 10, CH 4002, Basel, Switzerland
    Pharmacol Ther 93:79-98. 2002
  6. ncbi request reprint Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro
    Peter J Houghton
    Department of Molecular Pharmacology, St Jude Children s Research Hospital, Memphis, Tennessee 38105 2794, USA
    Cancer Res 64:2333-7. 2004
  7. ncbi request reprint Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition
    Ranjit K Goudar
    Department of Pathology, Duke University Medical Center, P O Box 2900, Durham, NC 27710, USA
    Mol Cancer Ther 4:101-12. 2005
  8. ncbi request reprint Integral role of the EGF receptor in HGF-mediated hepatocyte proliferation
    Lawrence A Scheving
    Department of Pediatrics, Medical Center, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
    Biochem Biophys Res Commun 290:197-203. 2002
  9. ncbi request reprint Salicylanilides as inhibitors of the protein tyrosine kinase epidermal growth factor receptor
    Christoph Liechti
    Department of Chemistry, University of Basel, St Johanns Ring 19, CH 4056 Basel, Switzerland
    Eur J Med Chem 39:11-26. 2004

Detail Information

Publications9

  1. ncbi request reprint Tyrosine kinase inhibitors: from rational design to clinical trials
    P Traxler
    Novartis Pharma AG, Oncology Research, CH 4002 Basel, Switzerland
    Med Res Rev 21:499-512. 2001
    ..In addition, potent inhibition of the PDGFR and c-Kit tyrosine kinases also indicates its possible clinical use in solid tumors...
  2. ncbi request reprint Tyrosine kinases as targets in cancer therapy - successes and failures
    Peter Traxler
    Novartis Pharma AG, Oncology Research, CH4002 Basel, Switzerland
    Expert Opin Ther Targets 7:215-34. 2003
    ....
  3. ncbi request reprint AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity
    Peter Traxler
    Oncology Research, Novartis Institutes for BioMedical Research, Klybeckstrasse, CH 4002 Basel, Switzerland
    Cancer Res 64:4931-41. 2004
    ..Consequently, AEE788 is currently in Phase I clinical trials in oncology...
  4. ncbi request reprint New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis
    G Bold
    Oncology Research, and Process Research, Novartis Pharma AG, CH 4002 Basel, Switzerland
    J Med Chem 43:2310-23. 2000
    ..Since these 1-anilino-(4-pyridylmethyl)phthalazines are orally well absorbed, these compounds qualify for further profiling and as candidates for clinical evaluation...
  5. ncbi request reprint Protein kinases as targets for anticancer agents: from inhibitors to useful drugs
    Doriano Fabbro
    Department of Oncology, Novartis Pharma Inc, WKL 125 4 10, CH 4002, Basel, Switzerland
    Pharmacol Ther 93:79-98. 2002
    ..Phase I/II studies demonstrated that STI571 is well tolerated, and that it showed promising hematological and cytogenetic responses in CML and clinical responses in the c-Kit-driven gastrointestinal tumors...
  6. ncbi request reprint Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro
    Peter J Houghton
    Department of Molecular Pharmacology, St Jude Children s Research Hospital, Memphis, Tennessee 38105 2794, USA
    Cancer Res 64:2333-7. 2004
    ..These results suggest that imatinib mesylate inhibits the function of ABCG2 but is not a substrate for this transporter...
  7. ncbi request reprint Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition
    Ranjit K Goudar
    Department of Pathology, Duke University Medical Center, P O Box 2900, Durham, NC 27710, USA
    Mol Cancer Ther 4:101-12. 2005
    ..These studies suggest that simultaneous inhibition of growth factor receptor and mTOR pathways offer increased benefit in glioma therapy...
  8. ncbi request reprint Integral role of the EGF receptor in HGF-mediated hepatocyte proliferation
    Lawrence A Scheving
    Department of Pediatrics, Medical Center, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
    Biochem Biophys Res Commun 290:197-203. 2002
    ..The mitogenic effect of HGF may be secondary to increased synthesis or processing of EGFR ligands such as TGF-alpha...
  9. ncbi request reprint Salicylanilides as inhibitors of the protein tyrosine kinase epidermal growth factor receptor
    Christoph Liechti
    Department of Chemistry, University of Basel, St Johanns Ring 19, CH 4056 Basel, Switzerland
    Eur J Med Chem 39:11-26. 2004
    ..Some of them indeed proved to be potent and selective EGFR tyrosine kinase inhibitors. The most potent ones being 28, 16, 20, 6, and 15, with IC(50) in the 23-71 nM range...